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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is becoming the major cause of liver disease-related morbidity and mortality in the United States and Europe ( 1, 2 ) . As recently demonstrated by Ekstedt et al. ( 3 ) , the most important determinant of outcomes including mortality for patients with NAFLD is their fi brosis stage. Accordingly, effi cient and eff ective identifi cation of patients with advanced fi brosis who are at risk for the complications of advanced liver disease and increased mortality is critical.
Th e optimal risk stratifi cation strategy for patients with NAFLD, however, is unknown.
American Association for the Study of Liver Disease (AASLD) guidelines recommend a liver biopsy for patients with metabolic syndrome or elevated NAFLD fi brosis scores (NFS)-a freely available algorithm based on the alanine and aspartate aminotransferase levels, albumin, platelet count, body mass index (BMI), and the presence of diabetes mellitus ( 4 ) . Clinicians and patients alike are deeply interested in alternative strategies to the liver biopsy for Identifi cation of patients with nonalcoholic fatty liver disease (NAFLD) who have advanced fi brosis is crucial. Vibration controlled transient elastography (VCTE) is an alternative to biopsy, although published experience with VCTE in a US population is limited.
METHODS:
We performed a prospective cohort of 164 biopsy-proven NAFLD patients evaluated with VCTE using an M probe and the NAFLD fi brosis score (NFS) at baseline and a repeat VCTE at 6 months. Reliable liver stiffness measurements (LSMs) were defi ned as 10 valid measurements and interquartile range ≤30% of the median.
RESULTS:
A total of 120 (73.2%) patients had reliable LSM. The median LSMs for patients with and without F3-F4 (advanced) fi brosis were 6.6 kPA (5.3-8.9) and 14.4 kPA (12.1-24.3), respectively. The optimal LSM cutoff for advanced fi brosis was 9.9 kPA (sensitivity 95% and specifi city 77%). In addition, 100% of patients with LSM<7.9 kPA did not have advanced fi brosis. A risk stratifi cation strategy based on VCTE avoids the need for biopsy in at least the 74 (45.1%) patients correctly classifi ed as low risk for advanced fi brosis. For the detection of F3-F4 fi brosis in patients with reliable VCTE, the area under the receiver operating curve (AUROC) is 0.93 (95% CI: 0.86-0.96). This is superior to the AUROC for the NFS (0.77), P =0.01. Patients who achieved a ≥5% weight loss at 6-month follow-up experienced improved LSM ( P =0.009), independent of the changes in aminotransferase levels.
a number of reasons. First, more than half of the patients off ered a liver biopsy refuse ( 5 ) . Second, biopsies are expensive and somewhat risky ( 6, 7 ) . Th ird, the liver biopsy is an imperfect gold standard. Sampling error is common ( 8 ) .
In clinical practice, it is diffi cult to base treatment and screening decisions based on the NFS alone. Its results benefi t from confi rmation. Vibration controlled transient elastography (VCTE) is a candidate confi rmatory test. An FDA approved, validated, point-of-care tool, VCTE can provide a non-invasive estimate of fi brosis in patients with NAFLD ( 9 ) . Furthermore, as demonstrated in two Italian cohorts by Petta et al. ( 10 ) , VCTE performs signifi cantly better in the detection of advanced fi brosis than NFS.
Although the published experience with VCTE in US is increasing, specifi c reports on NAFLD are lacking. Prior studies of patients with NAFLD from France and Canada reported good test performance in populations with BMI>30 kg/m 2 (11) (12) (13) . Still, many worry that the higher BMI of American patients may result in poorer VCTE performance. Herein, we report a prospective assessment of VCTE for American patients with NAFLD.
METHODS

Patient population
Th e subjects for this study were prospectively enrolled in an NAFLD registry at Beth Israel Deaconess Medical Center (BIDMC) beginning in 2009 through 2014. All patients had biopsy-proven NAFLD within 3 months of the VCTE examination. Patients with other chronic liver diseases or consumption of >20 g alcohol daily were excluded from the registry. At the time of this study, there were 185 subjects overall, 169 (91.4%) of whom had a VCTE exam within 3 months of a liver biopsy, 164 with an M-probe. We excluded the 5 patients who received XL probe VCTE exams to maintain a consistent protocol (the XL probe was only available for the fi nal 3 months of the study). Of these patients, 87 returned for a 6-month visit where a VCTE was performed. All patients received a comprehensive evaluation at study enrollment that included anthropomorphic indices (waist circumference, BMI) and lipid profi les in addition to their liverspecifi c testing.
As described elsewhere ( 14 ) , each patient received standard instructions for lifestyle modifi cations. Patients were instructed to perform 2 days of resistance/weight training weekly in addition to aerobic exercise. Th is included either 150 min of moderateintensity exercises (increased heart rate with sweating) or 75 min of vigorous-intensity exercises (sweating and hard breathing). Portion control, elimination of sugary beverages, and limited saturated fats were universally recommended. A consultation with a nutritionist was made available to all patients, and 33 (20%) attended at least one nutritionist visit during the fi rst 6 months of follow-up. No patient was receiving drug therapy (e.g., vitamin E) at the time of registration, nor were any prescribed during the fi rst 6 months of follow-up. Th e study was approved by the BIDMC institutional review board.
Liver biopsy
Ultrasound-guided liver biopsy was performed at the enrollment of the study. Biopsies were interpreted by specialized hepatopathologists and reported in a standardized manner according to the Brunt scoring system, with specifi c mention of fi brosis stage and the NAFLD activity score (NAS) as described previously ( 15 ) . NASH was defi ned by a NAS score of 5-8. Advanced liver fi brosis was defi ned as fi brosis stages 3-4. Pathologists were unaware of non-invasive assessments.
Non-invasive fi brosis assessment: VCTE and NFS
All VCTE examinations were performed with the "M" probe, which measures shear wave velocity at a depth of 25-65 mm ( 9, 16 ) . Th is velocity is converted mathematically into a liver stiffness measurement (LSM), which is depicted in kiloPascals (kPa). A successful VCTE exam was defi ned by the acquisition of 10 successful measurements where the interquartile range of the LSM does not exceed 30% of the median LSM. Th erefore, an "uninterpretable" VCTE examination encompassed failures on one or both accounts. Each patient received their exam aft er 3 h of fasting ( 9, 17 ) . All VCTE examinations were performed by two experienced technicians, both of whom have performed in excess of 500 LSMs. Each examination was reviewed by a physician to determine the adequacy of the measurements.
We used a strategy for non-invasive risk stratifi cation that classifi ed patients as low, indeterminate, and high risk for advanced fi brosis. Th is strategy enhances the negative predictive value while allowing for an indeterminate range of LSMs that deserve further evaluation. Th e optimal high-risk cutoff for advanced fi brosis was derived from this data set as described below. As is standard practice for non-invasive markers including the NFS and VCTE ( 9, 10, 18, 19 ) , we set the low-risk LSM cutoff for advanced fi brosis to be <80% of the optimal cutoff ( 9, 10, 18 ). An indeterminate LSM result was considered any value greater than a low-risk score and below the optimal cutoff for advanced fi brosis. For example, if the optimal cutoff for advanced fi brosis is determined to be 10 kPA, then a low-risk result would be<8 kPA and indeterminate would be 8-9.9 kPA.
All patients had their NFS score assessed at the time of their VCTE examination. Th e NFS was calculated according to the pub lished algorithm: −1.675+0.037×age (years)+0.094×BMI (kg/m 2 )+1.13× diabetes (yes=1, no=0)+0.99×AST/ALT ratio−0.013×platelet count (×10 9 /l)−0.66×albumin (g/dl) ( 19 ) . Th e NFS cutoff s consistent with advanced fi brosis and minimal fi brosis were 0.675 and −1.455, respectively, with the interval range considered indeterminate ( 19 ) . Th e presence of metabolic syndrome was determined using standard criteria based on waist circumference, triglyceride and high-density lipoprotein levels, blood pressure measurements, and the presence of diabetes or elevated fasting glucose ( 20 ) .
We compared the relative performance of non-invasive risk stratifi cation using VCTE alone and combined VCTE/NFS. Th e combination testing strategy with sequential VCTE and NFS assessments was studied as described elsewhere ( 9, 10, 21 ) . Specifi cally, patients would receive a VCTE examination during their clinic visit (at the point-of-care) and have blood tests performed to LIVER VCTE for NAFLD allow for the determination of their NFS. In this strategy, patients can be classifi ed as low risk if they have low-risk results from both VCTE and NFS, high risk if both tests provide concordant high risk results, or indeterminate if there is a discordance between tests or concordant indeterminate values. Risk stratifi cation strategies were evaluated based on their ability to exclude advanced fi brosis.
Outcomes
We chose multiple outcomes to report based on their interest to clinicians who utilize non-invasive tools. Our main goal was to assess the performance of risk stratifi cation strategies based on VCTE examinations, as well as combined testing with VCTE and NFS. To do so, we created clinical decision algorithms based on low-, indeterminate-, and high-risk LSM and NFS scores to determine the number of patients correctly classifi ed as low risk by VCTE alone or the combination strategy. High-risk LSM was defi ned as any score greater than the optimal LSM for the determination of advanced fi brosis as judged by the receiver operating characteristics (ROC) of LSM. We had three secondary goals. First, we sought to assess the determinants of uninterpretable VCTE exams. Exposure variables used for this analysis included all available baseline clinical characteristics with multivariate analysis of variables signifi cant on univariate comparisons to determine the primary drivers. Second, we explored the eff ect of clinical variables on LSM as continuous variable using linear regression. Th ird, we assessed changes in the LSM over time with a focus on the eff ect of weight loss. As we felt, a priori , that BMI, necroinfl ammatory activity (vis-à-vis ALT, AST, NAS score), and fi brosis burden could determine the capacity for LSM change, we divided our analyses into subsets to address these potential eff ects.
Data analysis
Data are summarized as mean±s.d. for normally distributed, median (25th and 75th percentiles) for non-normally distributed continuous outcomes, or counts and percentages for categorical outcomes. A two-tailed P -value was considered signifi cant when <0.05.
Logistic regression was performed to assess associations with the binary outcomes (uninterpretable VCTE, advanced fi brosis), with an odds ratio as its output. Linear regression was performed to assess continuous outcomes (LSMs). Multivariate analyses were performed to adjust for any variable found to be signifi cant on univariate analysis, defi ned either by and a P -value<0.05 or a confidence interval (CI) that did not cross 0. We also used ROC curves with 95% CIs to determine the optimal cutoff s for continuous measurements (LSM, BMI) for binary outcomes (advanced fi brosis, uninterpretable VCTE examinations). We compared the area under the ROC (AUROC) for diff erent diagnostic tests applied to the same patients within the data set using the non-parametric DeLong's test.
For univariate longitudinal assessments of LSM, we used paired Wilcoxon testing for matched-pairs to determine the signifi cance of the changes on follow-up. We chose to divide baseline subgroups based on patients with values greater than the median or based on the presence or absence of advanced histology (NASH or fi brosis). For change results, we chose a 5% reduction in weight as a clinically meaningful cutoff based on prior studies demonstrating a signifi cant reduction in hepatosteatosis with ≥5% weight loss ( 22 ) . We chose a 20% reduction in ALT or AST, as half of the cohort experienced such decrements. JMP Pro statistical discovery soft ware (version 11, SAS Institute, Cary, NC) was used for statistical analyses.
RESULTS
Determinants of liver stiffness reliability and results
Among the 164 patients with VCTE exams at enrollment, 120 (73.2%) had reliable results. Th e demographics and clinical details of the whole cohort as well as comparisons between those with reliable and uninterpretable exams are depicted in We then examined the 120 patients with reliable exams to determine the clinical drivers of LSM. Although univariate associations were present between LSM and age, BMI, diabetes, hypertension, AST, alkaline phosphatase, active histologic NASH, and advanced fi brosis, only advanced fi brosis held in multivariate analysis ( Table 2 ) . Among these patients, the median LSMs for patients with and without advanced fi brosis were 6.6 kPA (5.3-8.9) and 14.4 kPA (12.1-24.3), respectively.
Comparison of non-invasive testing strategies
Th e ability of non-invasive tests to discriminate patients at risk for advanced fi brosis was examined in two ways. First, we sought to describe VCTE's test characteristics. Th e optimal cutoff (9.9 kPA) has a sensitivity of 95% and a specifi city of 77% for advanced fi brosis. Th e positive and negative predictive values for this cutoff are 46.5 and 98.7%, respectively. Th e lowest LSM of a patient with advanced fi brosis was 8.4 kPA. Applying our pre-specifi ed criteria, low-risk results were those <7.9 kPA. Indeterminate LSM was defi ned as any value between 7.9 and 9.89 kPA. Th e specifi city and negative predictive value of the low-risk cutoff (<7.9 kPA) for advanced fi brosis are both 100%. A patient's LSM was associated with advanced fi brosis with an AUROC of 0.93 (95% CI 0.86-0.96).
Conversely, the AUROC for NFS was much lower: 0.77 (95% CI 0.63-0.97).Using the cutoff s mentioned by Angulo et al. ( 19 ) , high (0.675) and low (−1.455), the respective sensitivity and specifi city for advanced fi brosis were 19%/95% and 63%/70%, LIVER VOLUME 111 | MAY 2016
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respectively. Seven of 82 (9%) patients with low NFS had advanced fi brosis. Th e presence of metabolic syndrome was associated with an AUROC of 0.66 (95% CI 0.62-0.68). Comparing the AUROC from VCTE with NFS, VCTE is statistically superior, P =0.01, and led to a lower misclassifi cation rate (13 vs. 17%). When the NFS was applied to the whole cohort of 164 patients (not just those with reliable VCTE), the AUROC was lower at 0.72 (95% CI 0.60-0.82).
Second, we examined the performance of our non-invasive risk stratifi cation strategy with VCTE ( Figure 1 ). As above, 120 subjects had reliable M-probe VCTE exams. Of these, a low-risk VCTE result (<7.9 kPA) in 67 subjects (40.9% of the cohort) correctly classifi ed all as not having advanced fi brosis (100% correct classifi cation). Beyond that, patients were either classifi ed as high (43, 26.2% with >9.8 kPA) or indeterminate risk (10, 6 .1% with 7.9 to 9.8 kPA). A total of 46.5% of patients with high-risk LSM LIVER VCTE for NAFLD avoided using VCTE alone ( P =0.03). Additionally, the combination of VCTE and NFS does not improve indeterminate-or highrisk patient-risk stratifi cation further. For example, among the 10 patients with indeterminate VCTE exams, the 1 (10%) patient with advanced fi brosis had a low-risk NFS value. Similarly, for the 44 patients with uninterpretable VCTE exams, the prevalence of advanced liver disease among low-, indeterminate-, and high-risk NFS values was 14.3% (3/21), 13.3% (2/15), and 20% (2/5).
Subgroup analysis: sequential VCTE exams
Eighty-seven patients returned for VCTE examinations at 6 months ( Table 3 ). Th irty-seven (42.5%) patients had a 20% improvement in their LSM, whereas 17.2% had a 20% increase in LSM. Overall, patients experienced a 12.8% (95% CI 5.2-20.5) improvement in LSM. However, although many patients experienced an improvement in their LSM, the mean reduction in LSM was greater among those who lost ≥5% of their weight than those have advanced fi brosis (20/43) and 10% (1/10) of the patients with intermediate-risk LSM have advanced fi brosis. All 10 patients with indeterminate results had a follow-up LSM obtained 6 months later. Seven of the 10 had a repeat LSM of <7.9 kPA, and none with advanced fi brosis. Th e remaining 3 of the 10 patients had LSM >9.8 kPA, and one with advanced fi brosis. Th erefore, VCTEbased non-invasive risk stratifi cation with low-, indeterminate-, and high-risk scores therefore has a 100% sensitivity and a 75.5% specifi city. Overall, this strategy avoids the need for biopsy in at least the 74 (45.1% of the total cohort) patients correctly classifi ed as low risk for advanced fi brosis.
NFS alone and in combination with VCTE as risk stratifi cation strategies did not enhance risk stratifi cation in our cohort ( Supplementary Figure 1 online) . Concordant low-risk results between both VCTE and NFS resulted in 13 fewer patients or 54 (32.9%) patients being correctly classifi ed as low risk for advanced fi brosis. Th is is signifi cantly lower than the proportion of biopsies correctly Need further evaluation, recommend:
Low risk, recommend:
High risk, recommend:
Low risk, recommend: Figure 1 . Clinical decision making is aided by liver stiffness measurements (LSM). In this fl ow chart, depicting a non-invasive risk stratifi cation strategy using vibration controlled transient elastography (VCTE), we show how patients can be categorized as low, indeterminate, or high risk for advanced fi brosis in the fi rst clinical visit. We offer input on further management after risk stratifi cation. MRE, magnetic resonance elastography.
LIVER VOLUME 111 | MAY 2016
who did not-22.7% (95% CI 8.2-37.1) and 8.1% (95% CI −1.0 to 16.7), respectively, P =0.04. Overall, 14 of 31 (45%) patients with LSM ≥9.9 kPA experienced a decrease in LSM<9.9 kPA on follow-up compared with 5 of 56 (8.9%) who began <9.9 and became ≥9.9 kPA. As shown in Supplementary Figure 2 , the correlation between change in BMI and LSM was weak. However, changes in LSM classifi cation (advanced fi brosis or not) were most associated with weight loss. Weight loss was associated with an odds ratio of 5.40 (95% CI 1.22-38.6; P =0.02) for a change in LSM from ≥9.9 kPA to <9.9 kPA. Th e eff ect of a weight increase on LSM could not be assessed, as only two patients experienced a ≥5% weight gain. As shown in Table 3 , the LSMs at baseline and follow-up for various baseline subgroups were signifi cantly different for patients with NAS ≤4 and a steatosis score of 1. When change variables were examined, a 5% reduction in weight, but not a 20% reduction in ALT or AST, was signifi cantly associated with a decrease in LSM ( P =0.009).
DISCUSSION
NAFLD is a common, costly, and potentially morbid condition.
As the presence of advanced fi brosis in NAFLD is the strongest predictor of liver-related morbidity and mortality ( 3 ), an effi cient non-invasive risk stratifi cation strategy to identify patients at high risk for advanced fi brosis is essential. Although liver biopsy remains the gold standard, alternatives are urgently needed to reduce risks and costs, as well as to satisfy patient preferences. In this prospective cohort study of consecutive patients enrolled at an American NAFLD clinic, we demonstrate three major fi ndings. First, using a non-invasive risk stratifi cation strategy with VCTE is extremely eff ective at ruling out advanced fi brosis, more so than the NFS. VCTE is highly sensitive but not specifi c; NFS is relatively insensitive but highly specifi c. Second, many patients, namely those with markedly elevated BMI, are not candidates for VCTE with an M probe, but further study using the XL probe in this population is needed. Th ird, we show that when patients are followed longitudinally, a 5% weight loss is associated with a decrease in LSMs on 6-month follow-up. Th is study extends the developing literature on non-invasive risk stratifi cation in several important ways. First, although experience with VCTE is growing world-wide, data regarding its applicability in the American NAFLD population are limited. VCTE performance in other nations, mainly in Asia, has been encouraging. In a recent meta-analysis, the pooled sensitivity and specifi city of various LSM cutoff s for advanced fi brosis were 85% and 85%, respectively ( 11 ) . In our hands, a cutoff of 9.9 kPA has a sensitivity of 95% and a specifi city of 77% for the presence of advanced fi brosis. Applying our non-invasive risk stratifi cation strategy increases the sensitivity (and therefore negative predictive value) to 100% with a minimal decrement in specifi city (75.5%). Accordingly, our data show that, for patients with reliable exams, mainly those with a BMI of 36 kg/m 2 or lower, VCTE with an M probe is an excellent tool for which clinicians may discern low-from high-risk patients, avoiding the need for biopsy in 45% patients presenting for evaluation at a US NAFLD clinic.
Second, the addition of NFS to VCTE worsened the performance of our non-invasive risk stratifi cation strategy. On one hand, these results contrast with those of Petta et al. ( 23 ) , who demonstrated an incremental benefi t to combined NFS/VCTE testing. On the other, these results confi rm some of the pitfalls in the clinical use of the NFS. Th e retrospective study by Petta et al. ( 23 ) included two cohorts with lower BMI (27.4 and 29.3 kg/m 2 ) and falsely classifi ed 4% of patients as low risk (including 7.3% in one of the cohorts). Similarly, in its American validation study, the NFS also misclassifi ed low-risk patients (12% had advanced fi brosis) ( 19 ) . Furthermore, the performance of NFS in the detection of advanced fi brosis in our cohort was similar to that of most large studies of NFS including its validation study ( 19 ) , as well as to those of McPherson et al. ( 24 ) and Petta et al. ( 10 ) Th e incremental value of VCTE-what the NFS does not off er in this or prior studies-is the ability to confi dently exclude advanced fi brosis at the point-of-care. However, the available data suggest that the natural history of NAFLD is oft en mild ( 3, 25, 26 ) . For this reason, an NFSbased strategy that would fail to capture patients with advanced fi brosis is still cost eff ective ( 27 ) .
Th ird, we found that a BMI>36.65 kg/m 2 was associated with uninterpretable VCTE results using the M-probe. BMI has had confl icting eff ects on the performance of VCTE ( 23, 28, 29 ) . It is generally accepted that higher BMI is associated with a higher likelihood of failed VCTE. Notably, the mean BMI of our cohort was ( 32 ) and 33.0 in a Canadian study ( 12 ) . We show that 1 in 4 patients with NAFLD evaluated at an American liver referral center will have an uninterpretable VCTE exam, using the M probe. It should be noted, however, that an uninterpretable exam is not, by itself, indicative of increased risk, as advanced fi brosis and active NASH are evenly distributed between patients with reliable and uninterpretable results. Further research is needed to clarify the performance of VCTE in the US with studies utilizing the XL probe. For now, we place our results in the context of a non-invasive risk stratifi cation strategy using either MRE or liver biopsy in patients with uninterpretable VCTE.
Fourth, we demonstrate that a 5% weight loss was associated with a lower follow-up LSM. Indeed, patients with LSM consistent with advanced fi brosis who lost weight were more than fi vefold more likely to be reclassifi ed as non-advanced fi brosis on followup. As recently shown by Petta et al. ( 18 ) in one Italian cohort, hepatic steatosis is a partial driver of LSM. Notably, we found that only grade 1 steatosis is signifi cantly linked to liver stiff ness improvement following weight loss. As 5% weight loss has been shown to improve hepatosteatosis ( 22 ) , it is likely that those with grade 1 are most likely to experience that benefi t of possible LSM improvements in the short term.
Th ese data must be understood within the context of the study design. First, this study was performed at a referral center in the Northeastern United States. Although most of our patients were obese with 75% of the cohort between 29.4 and36.5 kg/m 2 , the baseline BMI of a given cohort is likely to determine the applicability of VCTE to one's practice. Th e prevalence of advanced fi brosis (17.7%) is likely higher than in general clinical practice, which may mean that an even higher proportion of patients will have low-risk LSM elsewhere. Second, VCTE may not be available in many settings where, therefore, NFS is a viable alternative. Th ird, we did not perform follow-up biopsies to assess histological changes concurrent with LSM changes to tease out what precisely (fi brosis, steatosis, or other factors) is accounting for the decrease in LSM. Th e weak overall correlation between changes in BMI and LSM suggests that there are important unmeasured determinants of longitudinal LSM changes including necroinfl ammation, fi brosis, and intra-or inter-observer variations ( 30 ) . However, 6 months are likely insuffi cient for changes in fi brosis and the lack of association between ALT and AST and a change in LSM indicates that we would have been unlikely to detect any changes in necroinfl ammatory activity. Fourth, the multivariable analysis of factors contributing to liver stiff ness suggests that there are unmeasured confounders of VCTE. Fift h, owing to confounding by liver biopsy's sampling variability, non-invasive metrics of liver fi brosis cannot distinguish fi brosis stages ( 9 ) . Binary risk categories (advanced fi brosis or not) are therefore more reliable and answer the most important question for patients and providers alike ( 3, 26, 27 ) . Finally, we did not assess the XL probe in this setting, which may allow for fewer uninterpretable/failed VCTE exams.
